Xcout InteleXoZymes Inc.
Operating within the United States, eXoZymes, Inc. is a pioneering synthetic biochemical enterprise. The company's primary innovation is SimplePath, a sophisticated platform engineered to synthesize a diverse spectrum of chemicals. This output encompasses essential pharmaceuticals, alternative fuels, advanced materials, food additives, and entirely new molecular entities. Integral to its design, the SimplePath platform incorporates distinct modules, each housing one or more enzymes that work synergistically to facilitate specific biocatalytic transformations. The firm was established in 2014 and maintains its corporate headquarters in Monrovia, California.
Subscribe to see eXoZymes Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
eXoZymes Inc. at a glance
eXoZymes Inc. is a biotech company headquartered in Monrovia, United States. It is publicly listed (EXOZ) with a market capitalisation of $51.4M. Xcout tracks 10 named people at eXoZymes Inc., including Michael Heltzen (President & Chief Executive Officer).
eXoZymes Inc. leadership
- Michael HeltzenPresident & Chief Executive Officer
- Damien A. PerrimanChief Commercial Officer
- Amy LunzerChief of Staff
- Tyler KormanCo-Founder & Chief Scientific Officer
- Paul OpgenorthCo-Founder & Vice President of Development
- James U. BowieFounder & Independent Director
4 more named people on record for eXoZymes Inc., with roles, board committees and tenure — see the full roster →
eXoZymes Inc. competitors
A few of eXoZymes Inc.'s closest competitors — see the full list of competitors and alternatives →
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
Aralez Bio is advancing greener therapeutic development by harnessing enzymes for biocatalysis and pharmaceutical applications. Headquartered in Berkeley, California, the company was recognized with the Excellence in Green Chemistry Award.
Hexagon Bio, Inc. is a biotechnology company headquartered in Menlo Park, California, that is developing natural crop protections. The company focuses on utilizing its proprietary technology and pipeline to discover novel products.
Antheia, Inc. is an advanced biotechnology research and biosynthesis company headquartered in Menlo Park, California, delivering 21st-century pharmaceutical solutions.
Optimvia is a biopharmaceutical company that utilizes its proprietary ADEPT discovery platform to engineer enzymes for synthesizing complex therapeutic molecules. The company's primary product is a commercially viable, biosynthetic alternative to animal-derived heparin, aimed at replacing traditional livestock-sourced supplies and developing novel heparin-based pharmaceuticals.
General Biotechnologies develops programmable synthetic biology platforms that use edible microbes to manufacture and deliver peptide therapeutics. The company primarily serves the pharmaceutical industry by reformulating discontinued peptide drugs into low-cost, needle-free oral medications and providing field-deployable biomanufacturing kits.
Get eXoZymes Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on eXoZymes Inc. in Xcout Intel
- 10 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access